LumiraDx Ltd Overview
Pro stress-test →LumiraDx Ltd was a UK-based point-of-care diagnostics company that developed portable testing platforms enabling rapid diagnostic testing in community settings. The company offered a broad menu of lab-comparable tests covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders. In January 2024, LumiraDx agreed to be acquired by Roche, leading to the delisting of its stock from Nasdaq.
Strategic Profile
Pro stress-test →LumiraDx leveraged actively controlled microfluidic technology to provide accessible diagnostic solutions at the point of care. The company pursued a platform consolidation strategy, particularly in European markets like the UK and Germany, expanding its installed base of diagnostic instruments and test menu. The acquisition by Roche positioned the technology within a major global diagnostics and pharmaceutical conglomerate.
Competitive Landscape
Pro stress-test →Before acquisition, LumiraDx competed in the point-of-care diagnostics market against companies like Abbott Diagnostics, Siemens Healthineers, Roche Diagnostics, and Alere (now part of Abbott). The company differentiated through its microfluidic platform enabling a broad test menu on a single portable device. Its acquisition by Roche consolidated a competitive threat and integrated the technology into Roche's extensive diagnostics portfolio.
Industry Context
LumiraDx Ltd operates in Point-of-care diagnostics platforms.
Key facts
Founded: 2014 · Headquarters: London, UK · Employees: N/A · Revenue: $254.5M (2022) · Market cap: N/A